Hiroshi Kagamu

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

Abstract Background In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation. Methods Pat...